scheduleThe Daily SynthesisToday

Saroglitazar Mg Achieves Key Phase II(b) Endpoint in Global MASH Trial

Saroglitazar Mg Achieves Primary Endpoint in Phase II(b) MASH Trial

Zydus reports Phase II(b) trial results for Saroglitazar Mg, showing a 26.5% treatment difference over placebo in clearing MASH without worsening fibrosis.

scienceVital Care Express Research

Read Full Report arrow_forward

Recent Articles

View all articles arrow_forward

A personalized mRNA cancer vaccine just passed its first phase 3 test in melanoma, and that has never happened before

Oncology

Merck and Moderna say their custom-built mRNA vaccine, added to Keytruda, cut the chance of melanoma coming back in a 1,137-patient phase 3 trial, the first time an individualized cancer vaccine has won a trial this size, though the companies have not yet shown the actual numbers

The phase 3 INTerpath-001 trial of Merck and Moderna's personalized mRNA cancer vaccine (intismeran autogene) plus Keytruda met its main goals in resected melanoma, the first phase 3 win for an individualized cancer vaccine.

A gene test just spared two thirds of high-risk breast cancer patients from chemotherapy, and the cancer came back no more often

Oncology

A 4,429-patient international trial let a 50-gene tumour test decide who needed chemotherapy for hormone-driven early breast cancer, and 68% safely skipped it with almost identical survival five years on

The OPTIMA trial used the 50-gene Prosigna test to guide chemo decisions in 4,429 ER-positive, HER2-negative early breast cancer patients, and 68% safely avoided chemotherapy with near-identical 5-year survival.

A promising sickle cell pain drug just failed its biggest test, and where you were treated mattered more than the drug

Conditions

A phase 3 trial gave 271 children and young adults intravenous arginine during a sickle cell pain crisis and found it did not shorten the crisis at all, while the hospital a child landed in mattered far more than whether they got the drug

A 2026 JAMA phase 3 trial (STArT) of 271 children and young adults found intravenous arginine did not shorten sickle cell pain crises, and hospital-to-hospital differences dwarfed any effect of the drug.

After a type 2 diabetes diagnosis, men and women get sick in different ways, and the care system treats them as if they do not

Conditions

A study of 28,720 UK adults tracked what happened after a type 2 diabetes diagnosis and found women slid toward mental health conditions while men hit heart and kidney disease earlier, yet both died sooner when diabetes and a mental health condition arrived together

A 2026 PLOS Medicine study of 28,720 UK adults found women after a type 2 diabetes diagnosis were more likely to develop anxiety or depression, while men hit heart and kidney disease earlier. Both died younger when a mental health condition was in the mix.

STAR-TREC Trial Shows 5-Week Chemoradiotherapy Spares 80% of Rectal Cancer Surgery

Oncology

An international trial of more than 500 early-stage rectal cancer patients found that a five-week course of chemoradiotherapy let four in five keep their rectum and avoid radical surgery at one year, sparing many a permanent stoma, though the long-term results are still to come

Results from the STAR-TREC trial show 80% of early-stage rectal cancer patients avoided radical surgery after a 5-week chemoradiotherapy regimen.

A simple at-home stool test was tied to a 43 percent lower risk of dying from bowel cancer, in one of Sweden's largest screening studies

Public Health

Tracking more than 376,000 people for up to 14 years, researchers at Karolinska Institutet found that people who actually did the free stool test had a 43% lower risk of dying from colorectal cancer, while simply being invited cut the risk 26%

A 2026 JAMA Network Open study of 376,511 people found active participation in Sweden's bowel cancer screening was linked to a 43% lower risk of dying from the disease, and an invitation alone to a 26% lower risk. What the numbers mean for you.